Immunology

Researchers at the Max Delbrück Center have found that a cellular housekeeping mechanism called autophagy plays a major role in ensuring that T stem cells undergo normal cell division. The findings, published in “Nature Cell Biology,” could help boost vaccine response in older adults.

Five scientists from the Max Delbrück Center have been named among the 100 most important minds in Berlin science in 2025 by the newspaper Tagesspiegel: Simone Spuler, Clara Vázquez García, Thoralf Niendorf, Gabriele Schiattarella and Ana Pombo.

The American Heart Association has awarded its Excellence Award for Hypertension Research to Dominik Müller from the Max Delbrück Center. He is only the third European to be honored with this distinction from the oldest professional society in the U.S.

The European Federation of Immunological Societies is awarding Klaus Rajewsky of the Max Delbrück Center its first-ever Lifetime Achievement Award. The 88-year-old Rajewsky, who remains active in research, is being recognized for his pioneering work in cellular and molecular immunology.

Can an aging immune system be coaxed into responding to vaccination like its’ younger self? In “Nature Aging,” Sebastian Hofer, Katja Simon and colleagues discuss emerging interventions that may boost older adults’ response to vaccines. They are also recruiting volunteers for a clinical trial of their own.

During a week-long course at the Gläsernes Labor, 24 teenagers delved into genetics, immunology, and allergic disease. The course marked the beginning of a new collaboration with the Max Delbrück Center, Charité – Universitätsmedizin Berlin, the German Center for Child and Adolescent Health and others.

A team led by Simon Haas has developed a technology to decode how immune cells talk to each other – revealing how our bodies respond to infections, how miscommunication can trigger autoimmune diseases, and why some people don’t respond to immunotherapies. The study was published in “Nature Methods.”

Oral immunotherapy helps many children with peanut allergy – but for some, it can also trigger severe allergic reactions. In the journal “Allergy”, a team led by Young-Ae Lee explains what might be behind these differences and how treatment could become more personalized.

Starting in 2027, Captain T Cell – a Max Delbrück Center biotech spin-off – will begin the first clinical trial of its TCR-T cell therapy. This has been made possible through funding from the National Center for Tumor Diseases and close collaboration with Charité – Universitätsmedizin Berlin.

Where does health end and illness begin – and what happens in between? Researchers working in the ImmunoPreCept Excellence Cluster are planning to take a deep look inside our cells and answer this question. In this interview, the coordinators explain what they hope to achieve in the next seven years.